IL148933A0 - Compositions and methods for tumor-targeted delivery of effector molecules - Google Patents

Compositions and methods for tumor-targeted delivery of effector molecules

Info

Publication number
IL148933A0
IL148933A0 IL14893300A IL14893300A IL148933A0 IL 148933 A0 IL148933 A0 IL 148933A0 IL 14893300 A IL14893300 A IL 14893300A IL 14893300 A IL14893300 A IL 14893300A IL 148933 A0 IL148933 A0 IL 148933A0
Authority
IL
Israel
Prior art keywords
tumor
compositions
methods
targeted delivery
effector molecules
Prior art date
Application number
IL14893300A
Original Assignee
Vion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc filed Critical Vion Pharmaceuticals Inc
Publication of IL148933A0 publication Critical patent/IL148933A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IL14893300A 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules IL148933A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15763799P 1999-10-04 1999-10-04
US15750099P 1999-10-04 1999-10-04
US15758199P 1999-10-04 1999-10-04
PCT/US2000/023242 WO2001025397A2 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules

Publications (1)

Publication Number Publication Date
IL148933A0 true IL148933A0 (en) 2002-09-12

Family

ID=27388022

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14893300A IL148933A0 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules

Country Status (11)

Country Link
EP (1) EP1261369A4 (en)
JP (1) JP2004500042A (en)
KR (1) KR20020059605A (en)
CN (1) CN1420783A (en)
AU (1) AU783714B2 (en)
BR (1) BR0014491A (en)
CA (1) CA2386465A1 (en)
IL (1) IL148933A0 (en)
MX (1) MXPA02003384A (en)
NZ (1) NZ518354A (en)
WO (1) WO2001025397A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9812079A (en) 1997-09-10 2000-09-26 Vion Pharmaceuticals Inc Salmonella sp. mutant, lipopolysaccharide, process to inhibit the growth or reduce the volume of a solid tumor cancer, pharmaceutical composition, and, improved process to select genetic alterations in a bacterium.
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
CA2869088A1 (en) * 2002-02-07 2003-08-14 Massachusetts Institute Of Technology Anti-pathogen treatments
CA2513251C (en) 2003-01-14 2013-03-19 Dana-Farber Cancer Institute Cancer therapy sensitizer
BRPI0411526A (en) * 2003-06-18 2006-08-01 Genelux Corp vaccinia virus and other modified recombinant microorganisms and uses thereof
WO2005012363A1 (en) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. Targeting inflammation inducer
CN100435850C (en) * 2004-03-22 2008-11-26 中国医学科学院血液学研究所 Combination of medication produced from attenuated salmonella bacteria possessing effect of radiation protection and anti tumour
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP1781096B1 (en) * 2004-06-29 2016-02-24 AntiCancer, Inc. Prostate cancer selective salmonella typhimurium auxotrophs
ITRM20050422A1 (en) * 2005-08-05 2007-02-06 Consiglio Nazionale Ricerche PROTEIN FACTORS DERMONECROTIZZANTI OF BACTERIAL ORIGIN AND RELATED USES IN MEDICAL FIELD.
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8357486B2 (en) 2008-01-11 2013-01-22 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
FR2960001A1 (en) 2010-05-12 2011-11-18 Univ Rennes RECOMBINANT VECTOR FOR THE PRODUCTION AND SECRETION OF AMINO ACID SEQUENCES OF INTEREST BY PROPIONIC BACTERIA AND ITS APPLICATIONS
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
CN102604949A (en) * 2011-04-12 2012-07-25 南京大学 Anaerobic tissue selective gene expression method driven by alcohol dehydrogenase promoter and application thereof
WO2013128288A1 (en) * 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
CN102731658B (en) * 2012-05-15 2014-07-30 山东大学 Tat PTD-Endostatin recombination protein, preparation method and application thereof
ES2759854T3 (en) * 2013-01-02 2020-05-12 Decoy Biosystems Inc Compositions and methods for cancer treatment using bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2829274A1 (en) 2013-07-25 2015-01-28 Institut National De La Recherche Agronomique Vectors for producing and secreting substance of interest by bacteria and applications thereof
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR101685034B1 (en) * 2015-04-10 2016-12-09 전남대학교 산학협력단 Solid cancer tissue targeting bacterium and use thereof
EP3402498A1 (en) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
CN107537027A (en) * 2016-06-23 2018-01-05 南开大学 TNFSF15 albumen is preparing the purposes in treating melanoma medicine
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MX2019008196A (en) * 2017-01-06 2019-12-16 Synlogic Operating Co Inc Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells.
CN107115533A (en) * 2017-04-01 2017-09-01 广州华津医药科技有限公司 Applications of the genetic engineering bacterium VNP20009 M in treatment malignant sarcomas medicine is prepared
US20200149053A1 (en) * 2017-07-12 2020-05-14 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
MY195280A (en) 2017-09-08 2023-01-12 New Portal Ltd Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability
CN108314741B (en) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 Tumor blood vessel targeted anti-cancer peptide NKL-DOTA and preparation method thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN110423772B (en) * 2019-07-17 2023-04-21 上海科技大学 Cytosine base editing plasmid for Acinetobacter baumannii and application of cytosine base editing plasmid
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114438111B (en) * 2020-11-05 2023-08-11 深圳先进技术研究院 Construction of PP2 strict anaerobic salmonella strain and application thereof in tumor treatment
WO2023041809A1 (en) * 2021-09-20 2023-03-23 Pulmobiotics, S.L. Genetically modified mycoplasma bacteria active against heterogenous bacterial biofilms
CN116676324B (en) * 2023-07-28 2023-10-27 四川大学华西医院 System and method for constructing and releasing anti-tumor effector protein based on Kil protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338679A3 (en) * 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
IL123569A (en) * 1995-09-06 2006-10-05 Dept Of The Army Attenuated shigella strain for delivering a mamalian expression plasmid into a mammalian cell
BR9812079A (en) * 1997-09-10 2000-09-26 Vion Pharmaceuticals Inc Salmonella sp. mutant, lipopolysaccharide, process to inhibit the growth or reduce the volume of a solid tumor cancer, pharmaceutical composition, and, improved process to select genetic alterations in a bacterium.
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Also Published As

Publication number Publication date
AU6933400A (en) 2001-05-10
EP1261369A2 (en) 2002-12-04
JP2004500042A (en) 2004-01-08
WO2001025397A3 (en) 2002-01-24
CA2386465A1 (en) 2001-04-12
EP1261369A4 (en) 2006-02-01
NZ518354A (en) 2005-02-25
KR20020059605A (en) 2002-07-13
WO2001025397A2 (en) 2001-04-12
AU783714B2 (en) 2005-12-01
MXPA02003384A (en) 2002-08-20
CN1420783A (en) 2003-05-28
BR0014491A (en) 2004-03-09

Similar Documents

Publication Publication Date Title
IL148933A0 (en) Compositions and methods for tumor-targeted delivery of effector molecules
AU7389300A (en) Methods of administration of glycopyrrolate compositions
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AUPQ419099A0 (en) Novel compositions and methods
AU4133701A (en) Methods and compositions for peptide synthesis
AU3192700A (en) Medicinal compositions
AU5326100A (en) Pharmaceutical compositions and methods for use
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU3864900A (en) Compositions and methods for their preparation from (lepidium)
AU2005300A (en) Medicinal compositions
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
AU5565099A (en) Pharmaceutical compositions and methods for use
AU6056500A (en) Process and composition for temporarily suppressing pain
HUP0105028A3 (en) Compositions having improved stability and process for their preparation
HUP0202729A3 (en) Compositions for parenteral use of estramustine phosphate and amino acids
AU1152601A (en) Compositions and their use
AUPQ197899A0 (en) Biomedical compositions
AU6094200A (en) Nor gene compositions and methods for use thereof
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU7836798A (en) Compositions for delivery of biological agents and methods for the preparation thereof
EP1163340A4 (en) Compositions and methods for the modification of gene expression
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU3774100A (en) Heat-activated cleaning compositions with wrinkle-resistance and methods of use
AU4543500A (en) Pharmaceutical compositions and uses
AU4709900A (en) Hmx compositions and processes for their preparation